Technical Analysis for CMPS - COMPASS Pathways Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -0.21% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Possible Inside Day | about 21 hours ago |
| 3x Volume Pace | about 23 hours ago |
| Down 5% | about 23 hours ago |
| 2x Volume Pace | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 10/31/2024
COMPASS Pathways Plc Description
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.
Classification
Sector: Healthcare
Industry: Medical Care Facilities
Keywords: Health Sciences Drug Discovery FDA Mental Health Psychoactive Drugs Entheogens Depression Major Depressive Disorder Breakthrough Therapy MP3 Treatment Resistant Depression Psilocybin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.75 |
| 52 Week Low | 4.05 |
| Average Volume | 731,416 |
| 200-Day Moving Average | 8.00 |
| 50-Day Moving Average | 6.60 |
| 20-Day Moving Average | 6.07 |
| 10-Day Moving Average | 6.01 |
| Average True Range | 0.43 |
| RSI (14) | 23.08 |
| ADX | 22.46 |
| +DI | 8.63 |
| -DI | 43.69 |
| Chandelier Exit (Long, 3 ATRs) | 5.33 |
| Chandelier Exit (Short, 3 ATRs) | 5.33 |
| Upper Bollinger Bands | 6.99 |
| Lower Bollinger Band | 5.15 |
| Percent B (%b) | -0.21 |
| BandWidth | 30.39 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.17 |
| MACD Histogram | -0.1215 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.29 | ||||
| Resistance 3 (R3) | 5.26 | 5.04 | 5.20 | ||
| Resistance 2 (R2) | 5.04 | 4.91 | 5.06 | 5.17 | |
| Resistance 1 (R1) | 4.90 | 4.82 | 4.93 | 4.93 | 5.14 |
| Pivot Point | 4.68 | 4.68 | 4.70 | 4.70 | 4.68 |
| Support 1 (S1) | 4.54 | 4.55 | 4.57 | 4.57 | 4.36 |
| Support 2 (S2) | 4.32 | 4.46 | 4.34 | 4.33 | |
| Support 3 (S3) | 4.18 | 4.32 | 4.30 | ||
| Support 4 (S4) | 4.21 |
